Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315)Adel Mandl, Jan H. Beumer, Lakshmana Das et al.|The Oncologist|2026Cited by 0